Persistent inflammation and recovery after intensive care: A systematic review

Journal of Critical Care

Volumn 33, Issue , 2016, Pages 192-199

  Griffith, David M ^a   Vale, Matthew E ^a   Campbell, Christine ^a   Lewis, Steff ^a   Walsh, Timothy S ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Critical illness; Inflammation; Intensive care; Quality of life; Recovery; Rehabilitation

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MYELOPEROXIDASE; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 7; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 8; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRITICALLY ILL PATIENT; HOSPITAL DISCHARGE; HUMAN; INFLAMMATION; INTENSIVE CARE; INTENSIVE CARE UNIT; PREVALENCE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; QUALITY OF LIFE; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; CRITICAL ILLNESS; META ANALYSIS;

CRITICAL CARE; CRITICAL ILLNESS; HUMANS; INFLAMMATION; INTENSIVE CARE UNITS; PATIENT DISCHARGE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84957613043     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2016.01.011     Document Type: Article

References (67)

1. Audit of Critical Care in Scotland Reporting on 2010, Scottish Intensive Care Society Audit Group 2011.
2. Herridge M.S. Legacy of intensive care unit-acquired weakness. Crit Care Med 2009, 37:S457-S461.
3. Griffiths R.D., Hall J.B. Intensive care unit-acquired weakness. Crit Care Med 2010, 38:1619. 10.097/CCM.0b013e3181ddc578.
4. De Jonghe B., Sharshar T., Lefaucheur J.-P., Authier F.-J., Durand-Zaleski I., Boussarsar M., et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002, 288:2859-2867.
5. Coakley J.H., Nagendran K., Honavar M., Hinds C.J. Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis. Intensive Care Med 1993, 19:323-328.
6. Fong Y., Moldawer L.L., Marano M., Wei H., Barber A., Manogue K., et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989, 256:R659-R665.
7. Hoshino E., Pichard C., Greenwood C.E., Kuo G.C., Cameron R.G., Kurian R., et al. Body composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Physiol 1991, 260:E27-E36.
8. Baracos V., Rodemann H.P., Dinarello C.A., Goldberg A.L. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med 1983, 308:553-558.
9. Flores E.A., Bistrian B.R., Pomposelli J.J., Dinarello C.A., Blackburn G.L., Istfan N.W. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Investig 1989, 83:1614-1622.
10. Goodman M.N. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 1991, 260:E727-E730.
11. Llovera M., Lopez-Soriano F.J., Argiles J.M. Chronic tumour necrosis factor-alpha treatment modifies protein turnover in rat tissues. Biochem Mol Biol Int 1993, 30:29-36.
12. Goodman M.N. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994, 205:182-185.
13. Charters Y., Grimble R.F. Effect of recombinant human tumour necrosis factor alpha on protein synthesis in liver, skeletal muscle and skin of rats. Biochem J 1989, 258:493-497.
14. Miller S.C., Ito H., Blau H.M., Torti F.M. Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol 1988, 8:2295-2301.
15. Zamir O., Hasselgren P.O., James H., Higashiguchi T., Fischer J.E. Effect of tumor necrosis factor or interleukin-1 on muscle amino acid uptake and the role of glucocorticoids. Surg Gynecol Obstet 1993, 177:27-32.
16. Visser M., Pahor M., Taaffe D.R., Goodpaster B.H., Simonsick E.M., Newman A.B., et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002, 57:M326-M332.
17. Barbieri M., Ferrucci L., Ragno E., Corsi A., Bandinelli S., Bonafe M., et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 2003, 284:E481-E487.
18. Roubenoff R., Parise H., Payette H.A., Abad L.W., D'Agostino R., Jacques P.F., et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med 2003, 115:429-435.
19. Schaap L.A., Pluijm S.M.F., Deeg D.J.H., Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006, 119:526.e9-526.e17.
20. Schaap L.A., Pluijm S.M.F., Deeg D.J.H., Harris T.B., Kritchevsky S.B., Newman A.B., et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009, 64:1183-1189.
21. Eid A.A., Ionescu A.A., Nixon L.S., Lewis-Jenkins V., Matthews S.B., Griffiths T.L., et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1414-1418.
22. Yende S., Waterer G.W., Tolley E.A., Newman A.B., Bauer D.C., Taaffe D.R., et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006, 61:10-16.
23. DeJong C.H.C., Busquets S., Moses A.G.W., Schrauwen P., Ross J.A., Argiles J.M., et al. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep 2005, 14:257-263.
24. Toth M.J., Ades P.A., Tischler M.D., Tracy R.P., LeWinter M.M. Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. Int J Cardiol 2006, 109:179-187.
25. Raj D.S.C., Shah H., Shah V.O., Ferrando A., Bankhurst A., Wolfe R., et al. Markers of inflammation, proteolysis, and apoptosis in ESRD. Am J Kidney Dis 2003, 42:1212-1220.
26. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
27. Hoy D., Brooks P., Woolf A., Blyth F., March L., Bain C., Baker P., et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012, 65:934-939.
28. Shamliyan T.A., Kane R.L., Ansari M.T., Raman G., Berkman N.D., Grant M., et al. Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol 2011, 64:637-657.
29. Akbas T., Karakurt S., Unluguzel G., Celikel T., Akalin S. The endocrinologic changes in critically ill chronic obstructive pulmonary disease patients. COPD 2010, 7:240-247.
30. Al-Subaie N., Reynolds T., Myers A., Sunderland R., Rhodes A., Grounds R.M., et al. C-reactive protein as a predictor of outcome after discharge from the intensive care: a prospective observational study. Br J Anaesth 2010, 105:318-325.
31. Azevedo L., Ranzani O., Prada L., Azmpieri F., Pinaffi J., Battaini L., et al. C-reactive protein/albumin ratio at ICU discharge as a predictor of post-ICU death: a new useful tool. Critical Care Conference: 6th International Symposium on Intensive Care and Emergency Medicine for Latin America Sao Paulo Brazil. Conference Start: 20110622 Conference End: 5. Conference Publication: (var.pagings) 2011, 15. [pp 26].
32. Balci C., Sivaci R., Akbulut G., Karabekir H.S. Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. J Int Med Res 2009, 37:1709-1717.
33. Bateman A.P., McArdle F., Walsh T.S. Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis. Crit Care Med 2009, 37:1906-1912.
34. Damas P., Garweg C., Monchi M., Nys M., Canivet J.L., Ledoux D., et al. Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. Crit Care 2006, 10:R52. 10.1186/cc4879.
35. Grander W., Dunser M., Stollenwerk B., Siebert U., Dengg C., Koller B., et al. C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. Chest 2010, 138:856-862.
36. Hansen T.K., Thiel S., Wouters P.J., Christiansen J.S., Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003, 88:1082-1088.
37. Hekimoglu Sahin S., Memis D., Sut N. High C-reactive protein and amylase levels as prognostic markers in non-pancreatic severe sepsis patients. Trakya Univ Tip Fak Derg 2009, 26:9-17.
38. Ho K.M., Dobb G.J., Lee K.Y., Towler S.C., Webb S.A. C-reactive protein concentration as a predictor of intensive care unit readmission: a nested case-control study. J Crit Care 2006, 21:259-265.
39. Ho K.M., Lee K.Y., Dobb G.J., Webb S.A.R. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a prospective cohort study. Intensive Care Med 2008, 34:481-487.
40. Iapichino G., Marzorati S., Umbrello M., Baccalini R., Barassi A., Cainarca M., et al. Daily monitoring of biomarkers of sepsis in complicated long-term ICU-patients: can it support treatment decisions?. Minerva Anestesiol 2010, 76:814-823.
41. Iapichino G., Umbrello M., Albicini M., Spanu P., Bellani G., Polli F., et al. Time course of endogenous nitric oxide inhibitors in severe sepsis in humans. Minerva Anestesiol 2010, 76:325-333.
42. Kaben A., Correa F., Reinhart K., Settmacher U., Gummert J., Kalff R., et al. Readmission to a surgical intensive care unit: incidence, outcome and risk factors. Crit Care 2008, 12:R123. 10.1186/cc7023.
43. Litton E., Ho K.M., Chamberlain J., Dobb G.J., Webb S.A.R. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a nested case-control study. Crit Care Resusc 2007, 9:19-25.
44. Makris N., Dulhunty J.M., Paratz J.D., Bandeshe H., Gowardman J.R. Unplanned early readmission to the intensive care unit: a case-control study of patient, intensive care and ward-related factors. Anaesth Intensive Care 2010, 38:723-731.
45. Martensson J., Bell M., Oldner A., Xu S., Venge P., Martling C.-R. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 2010, 36:1333-1340.
46. Memis D., Gursoy O., Tasdogan M., Sut N., Kurt I., Ture M., et al. High C-reactive protein and low cholesterol levels are prognostic markers of survival in severe sepsis. J Clin Anesth 2007, 19:186-191.
47. Povoa P., Coelho L., Almeida E., Fernandes A., Mealha R., Moreira P., et al. Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Crit Care 2006, 10:R63.
48. Silvestre J., Coelho L., Povoa P. Should C-reactive protein concentration at ICU discharge be used as a prognostic marker?. BMC Anesthesiol 2010, 10. http://www.biomedcentral.com/1471-2253/10/17.
49. Van den Berghe G., Wilmer A., Hermans G., Meersseman W., Wouters P.J., Milants I., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006, 354:449-461.
50. Watanabe E., Hirasawa H., Oda S., Shiga H., Matsuda K., Nakamura M., et al. Cytokine-related genotypic differences in peak interleukin-6 blood levels of patients with SIRS and septic complications. J Trauma 2005, 59:1181-1189. [discussion 9-90].
51. Cho Y.J., Ham H.S., Jong K.H., Kim H.C., Lee J.D., Hwang Y.S. Usefulness of troponin-I, lactate, C-reactive protein as a prognostic markers in critically ill non-cardiac patients. [Korean]. Tuberc Respir Dis 2005, 58:562-569.
52. de Pablo R., Monserrat J., Reyes E., Diaz-Martin D., Rodriguez Zapata M., Carballo F., et al. Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules. J Intensive Care Med 2011, 26:125-132.
53. Jensen J.U., Heslet L., Jensen T.H., Espersen K., Steffensen P., Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006, 34:2596-2602.
54. Kauss I.A.M., Grion C.M.C., Cardoso L.T.Q., Anami E.H.T., Nunes L.B., Ferreira G.L., et al. The epidemiology of sepsis in a Brazilian teaching hospital. Braz J Infect Dis 2010, 14:264-270.
55. Oda S., Hirasawa H., Shiga H., Nakanishi K., Matsuda K.I., Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 2005, 29:169-175.
56. Povoa P., Teixeira-Pinto A., Carneiro A. C-reactive protein as an early marker of sepsis resolution: results from the Portuguese Community-acquired Sepsis Study (SACiUCI study). Crit Care 2011, 15:S96-S97.
57. Reny J.-L., Vuagnat A., Ract C., Benoit M.-O., Safar M., Fagon J.-Y. Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables. Crit Care Med 2002, 30:529-535.
58. Tsangaris I., Plachouras D., Kavatha D., Gourgoulis G.M., Tsantes A., Kopterides P., et al. Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis 2009, 9:213.
59. Tsuruta R., Nakahara T., Miyauchi T., Kutsuna S., Ogino Y., Yamamoto T., et al. Prevalence and associated factors for delirium in critically ill patients at a Japanese intensive care unit. Gen Hosp Psychiatry 2010, 32:607-611.
60. Umbrello M., Formenti P., Carloni E., Taverna M., Borotto E., Palmisano D., et al. Time course of endogenous nitric oxide inhibitors in human severe sepsis. Intensive Care Med 2010, 36:S432.
61. Weimann A., Bastian L., Bischoff W.E., Grotz M., Hansel M., Lotz J., et al. Influence of arginine, omega-3 fatty acids and nucleotide-supplemented enteral support on systemic inflammatory response syndrome and multiple organ failure in patients after severe trauma. Nutrition 1998, 14:165-172.
62. Yousef A.A., Amr Y.M., Suliman G.A. The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-alpha in critically ill patients: a prospective observational study. Crit Care 2010, 14:R33. 10.1186/cc8911.
63. Yucel T., Memis D., Karamanlioglu B., Sut N., Yuksel M. The prognostic value of atrial and brain natriuretic peptides, troponin I and C-reactive protein in patients with sepsis. Exp Clin Cardiol 2008, 13:183-188.
64. Woehrle T., Du W., Goetz A., Hsu H.-Y., Joos T.O., Weiss M., et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2008, 41:322-329.
65. Zenahlikova Z., Kvasnicka J., Kudrnova Z., Sudrova M., Brzezkova R., Mazoch J., et al. FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients. Clin Appl Thromb Hemost 2010, 16:584-590.
66. Woehrle T., Du W., Goetz A., Hsu H.-Y., Joos T.O., Weiss M., et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2008, 41:322-329.
67. Shamliyan T., Kane R.L., Dickinson S. A systematic review of tools used to assess the quality of observational studies that examine incidence or prevalence and risk factors for diseases. J Clin Epidemiol 2010, 63:1061-1070.